A novel class of self-complementary AAV vectors with multiple advantages based on cceAAV lacking mutant ITR

dc.contributor.authorZhang, Junping
dc.contributor.authorFrabutt, Dylan A.
dc.contributor.authorChrzanowski, Matthew
dc.contributor.authorLi, Ning
dc.contributor.authorMiller, Lohra M.
dc.contributor.authorTian, Jiahe
dc.contributor.authorMulcrone, Patrick L.
dc.contributor.authorLam, Anh K.
dc.contributor.authorDraper, Benjamin E.
dc.contributor.authorJarrold, Martin F.
dc.contributor.authorHerzog, Roland W.
dc.contributor.authorXiao, Weidong
dc.contributor.departmentPediatrics, School of Medicine
dc.date.accessioned2024-06-11T10:45:59Z
dc.date.available2024-06-11T10:45:59Z
dc.date.issued2024-02-03
dc.description.abstractSelf-complementary AAV vectors (scAAV) use a mutant inverted terminal repeat (mITR) for efficient packaging of complementary stranded DNA, enabling rapid transgene expression. However, inefficient resolution at the mITR leads to the packaging of monomeric or subgenomic AAV genomes. These noncanonical particles reduce transgene expression and may affect the safety of gene transfer. To address these issues, we have developed a novel class of scAAV vectors called covalently closed-end double-stranded AAV (cceAAV) that eliminate the mITR resolution step during production. Instead of using a mutant ITR, we used a 56-bp recognition sequence of protelomerase (TelN) to covalently join the top and bottom strands, allowing the vector to be generated with just a single ITR. To produce cceAAV vectors, the vector plasmid is initially digested with TelN, purified, and then subjected to a standard triple-plasmid transfection protocol followed by traditional AAV vector purification procedures. Such cceAAV vectors demonstrate yields comparable to scAAV vectors. Notably, we observed enhanced transgene expression as compared to traditional scAAV vectors. The treatment of mice with hemophilia B with cceAAV-FIX resulted in significantly enhanced long-term FIX expression. The cceAAV vectors hold several advantages over scAAV vectors, potentially leading to the development of improved human gene therapy drugs.
dc.eprint.versionFinal published version
dc.identifier.citationZhang J, Frabutt DA, Chrzanowski M, et al. A novel class of self-complementary AAV vectors with multiple advantages based on cceAAV lacking mutant ITR. Mol Ther Methods Clin Dev. 2024;32(1):101206. Published 2024 Feb 3. doi:10.1016/j.omtm.2024.101206
dc.identifier.urihttps://hdl.handle.net/1805/41387
dc.language.isoen_US
dc.publisherElsevier
dc.relation.isversionof10.1016/j.omtm.2024.101206
dc.relation.journalMolecular Therapy - Methods & Clinical Development
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourcePMC
dc.subjectAdeno-associated virus
dc.subjectSelf-complementary AAV vectors
dc.subjectCovalently closed-end double-stranded AAV
dc.subjectTransduction
dc.subjectGenome integrity
dc.titleA novel class of self-complementary AAV vectors with multiple advantages based on cceAAV lacking mutant ITR
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Zhang2024NovelClass-CCBYNCND.pdf
Size:
2.57 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: